US10058536 — Pharmaceutical composition containing mirabegron
Method of Use · Assigned to Astellas Pharma Inc · Expires 2036-03-31 · 10y remaining
What this patent protects
This patent protects a pharmaceutical composition containing a complex of mirabegron or a salt thereof with sodium polystyrene sulfonate.
USPTO Abstract
To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate.
Drugs covered by this patent
- Myrbetriq (MIRABEGRON) · Apgdi
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3108 |
— | Myrbetriq |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.